Zheng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zheng Li has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Yue Hu
Department of Paediatric Genetics, Endocrinology and Metabolism, Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
9 shared publications - Bingwen Zou
Department of Radiation Oncology, Cancer Center & Institution of Stress Medicine, West China Hospital, Sichuan University, Chengdu, China
7 shared publications - Yi Zhang
Division of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
6 shared publications - Xinran Cheng
Department of Paediatric Genetics, Endocrinology and Metabolism, Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
5 shared publications - Qiang Li
Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China
4 shared publications Weilan He
Department of Paediatric Genetics, Endocrinology and Metabolism, Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
3 shared publications
Latest Publications
- 14 November 2026
- Published by Wiley in Advanced Materials
Materials Control of Nitric Oxide in Cancer Immunotherapy
Nitric oxide (NO) can suppress antitumor immunity, support tumor adaptation, or promote immune‐mediated killing, making its therapeutic manipulation highly dependent on exposure. This Review examines how materials control NO source, localization, release kinetics, and chemical fate in cancer immunotherapy, with particular attention to immune checkpoint blockade (ICB). We analyze polymeric donors, nanocarriers, injectable depots, and strategies for restricting endogenous NO production, linking their physicochemical properties to target exposure and immune function. Evidence from checkpoint‐treated models is distinguished from mechanisms established with other therapies and from human associations. Comparative analyses separate donor capacity from measured NO exposure, carrier accumulation from cellular delivery, and distant‐tumor control from demonstrated immune memory. Four overlapping endogenous contexts, comprising tumor adaptation, myeloid suppression, vascular dysfunction, and inflammatory effector activity, guide intervention design without constituting validated patient categories. We identify testable predictions concerning cellular selectivity, release kinetics, and spatial pharmacodynamic responses. Translation requires measurements that connect material behavior to a defined NO‐dependent process while demonstrating preservation of beneficial endothelial and immune functions. This framework provides a basis for evaluating when localized NO delivery or selective inhibition may support ICB, while recognizing the limits of current preclinical and clinical evidence.
- 14 November 2026
- Published by Wiley in Advanced Materials
Materials Control of Nitric Oxide in Cancer Immunotherapy
Nitric oxide (NO) can suppress antitumor immunity, support tumor adaptation, or promote immune‐mediated killing, making its therapeutic manipulation highly dependent on exposure. This Review examines how materials control NO source, localization, release kinetics, and chemical fate in cancer immunotherapy, with particular attention to immune checkpoint blockade (ICB). We analyze polymeric donors, nanocarriers, injectable depots, and strategies for restricting endogenous NO production, linking their physicochemical properties to target exposure and immune function. Evidence from checkpoint‐treated models is distinguished from mechanisms established with other therapies and from human associations. Comparative analyses separate donor capacity from measured NO exposure, carrier accumulation from cellular delivery, and distant‐tumor control from demonstrated immune memory. Four overlapping endogenous contexts, comprising tumor adaptation, myeloid suppression, vascular dysfunction, and inflammatory effector activity, guide intervention design without constituting validated patient categories. We identify testable predictions concerning cellular selectivity, release kinetics, and spatial pharmacodynamic responses. Translation requires measurements that connect material behavior to a defined NO‐dependent process while demonstrating preservation of beneficial endothelial and immune functions. This framework provides a basis for evaluating when localized NO delivery or selective inhibition may support ICB, while recognizing the limits of current preclinical and clinical evidence.
- 4 August 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , E96-E97
Letter to the Editor: Blood pressure adjustment and competing risks analysis should be reconsidered in the mortality exploration among children with MASLD
- 4 August 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , E96-E97
Letter to the Editor: Blood pressure adjustment and competing risks analysis should be reconsidered in the mortality exploration among children with MASLD
- 24 February 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 82 (1) , E11-E12
Letter to the Editor: Different phenotypes of CMRFs lead to different pathophysiological processes among individuals with MASLD/MetALD
An abstract is unavailable. This article is available as a PDF only.
- 24 February 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 82 (1) , E11-E12
Letter to the Editor: Different phenotypes of CMRFs lead to different pathophysiological processes among individuals with MASLD/MetALD
An abstract is unavailable. This article is available as a PDF only.
- 21 October 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (2) , e95-e97
Is MetALD an independent risk factor of all-cause mortality? A meta-analysis of 164,694 individuals from the real world
- 21 October 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (2) , e95-e97
Is MetALD an independent risk factor of all-cause mortality? A meta-analysis of 164,694 individuals from the real world
- 23 September 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (1) , e29-e31
Is MASLD a real culprit for all-cause mortality? A meta-analysis and preliminary pathophysiology exploration in the real world
- 23 September 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (1) , e29-e31
Is MASLD a real culprit for all-cause mortality? A meta-analysis and preliminary pathophysiology exploration in the real world
- 24 July 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (1) , E21-E22
Letter to the Editor: Aspirin and GLP-1RAs—The missing confounders of empagliflozin for MASLD without diabetes mellitus?
An abstract is unavailable. This article is available as a PDF only.
- 24 July 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (1) , E21-E22
Letter to the Editor: Aspirin and GLP-1RAs—The missing confounders of empagliflozin for MASLD without diabetes mellitus?
An abstract is unavailable. This article is available as a PDF only.
- 17 July 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 80 (4) , E48-E49
Letter to the Editor: The causal analysis of missing confounding factors for the association between HDV and specific liver events
An abstract is unavailable. This article is available as a PDF only.
- 17 July 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 80 (4) , E48-E49
Letter to the Editor: The causal analysis of missing confounding factors for the association between HDV and specific liver events
An abstract is unavailable. This article is available as a PDF only.
- 17 June 2024
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 18 (13-14) , 619-628
Prognostic value of NOB1 expression levels in various cancers: a systematic review and meta-analysis
Aim: This study evaluates the prognostic significance of NOB1 expression levels in various cancers.
- 17 June 2024
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 18 (13-14) , 619-628
Prognostic value of NOB1 expression levels in various cancers: a systematic review and meta-analysis
Aim: This study evaluates the prognostic significance of NOB1 expression levels in various cancers.
- 12 June 2024
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (21) , 1505-1514
Prognostic significance of FAT10 expression in malignant tumors: a systematic review and meta-analysis
Aim: FAT10, a ubiquitin-like modifier protein, influences apoptosis, DNA damage response and tumor growth, with unclear effects on cancer prognosis.Methods: We reviewed FAT10 expression's impact on malignancy prognosis through a systematic review and meta-analysis, including studies up to September 2023 from PubMed, EMBASE and Web of Science.Results: From 18 studies involving 2513 patients, FAT10 overexpression significantly reduced overall and disease-free survival across various tumors, indicating correlations with advanced disease stage, poor differentiation, lymph node metastasis and larger tumor size.Conclusion: FAT10's overexpression suggests a negative prognostic value in cancer, meriting further investigation.PROSPERO Registration Number: CRD42023431287.
- 12 June 2024
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (21) , 1505-1514
Prognostic significance of FAT10 expression in malignant tumors: a systematic review and meta-analysis
Aim: FAT10, a ubiquitin-like modifier protein, influences apoptosis, DNA damage response and tumor growth, with unclear effects on cancer prognosis.Methods: We reviewed FAT10 expression's impact on malignancy prognosis through a systematic review and meta-analysis, including studies up to September 2023 from PubMed, EMBASE and Web of Science.Results: From 18 studies involving 2513 patients, FAT10 overexpression significantly reduced overall and disease-free survival across various tumors, indicating correlations with advanced disease stage, poor differentiation, lymph node metastasis and larger tumor size.Conclusion: FAT10's overexpression suggests a negative prognostic value in cancer, meriting further investigation.PROSPERO Registration Number: CRD42023431287.
- 5 June 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 80 (5) , E74-E75
Letter to the Editor: New confounders emerging with new evidence regarding reduced HCC and improved survival
An abstract is unavailable. This article is available as a PDF only.
- 5 June 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 80 (5) , E74-E75
Letter to the Editor: New confounders emerging with new evidence regarding reduced HCC and improved survival
An abstract is unavailable. This article is available as a PDF only.